1. In patients with lung cancer on immune checkpoint inhibitor (ICI) who develop Common Terminology Criteria for Adverse Events (CTCAE) grade 1 or 2 myocarditis, continuation of ICI therapy was associated with low recurrence rates and improved overall survival (OS).
Evidence Rating Level: 2 (Good)
ICIs have dramatically altered the landscape of cancer treatment in recent years across many solid organ malignancies. However, use of ICIs is associated with several adverse events among which ICI-induced myocarditis is one of the most severe. It is currently unclear whether re-challenge with ICI in patients who develop ICI-induced myocarditis is safe. This retrospective cohort study therefore sought to investigate the safety and efficacy of ICI continuation among patients with lung cancer who develop CTCAE grade 1 or 2 myocarditis. Data from 357 patients (median[IQR] age, 67[61-71] year; 84.6% male) from Shanghai, China with lung cancer treated with ICIs who developed CTCAE grade 1 or 2 myocarditis between 2016 and 2024 were included in the study. During a median follow-up of 18 months, 8.8% of patients who continued immunotherapy (20/226) developed recurrent myocarditis. All cases of myocarditis were mild and classified as either CTCAE grade 1 or 2. Under multivariate Cox regression analysis, continuation of ICI was associated with significantly improved OS (hazard ratio, 0.45; 95% CI, 0.30-0.67; p < 0.001). Overall, this study found that among patients with lung cancer who developed grade 1 or 2 ICI-induced myocarditis, continuation of immunotherapy was associated with low recurrence of myocarditis and improved OS.
Click here to read this study in BMC Medicine
Citation: Liu Z, Song X, Fan Z, Lou Y, Kuang Y, Li R, et al. Immunotherapy continuation after mild immune checkpoint inhibitor-associated myocarditis in lung cancer: a retrospective cohort study. BMC Med. 2026 Nov 11. doi: 10.1186/s12916-026-05393-8. Epub ahead of print.
© 2026 2 Minute Medicine, Inc. All rights reserved. No part of this article may be reproduced, distributed or transmitted in any form or by any means without the prior written permission of 2 Minute Medicine, Inc. To license this content, contact 2 Minute Medicine, Inc. This article is for informational and educational purposes only; it is not medical advice and does not replace the judgment of a qualified healthcare professional.
Image: © 2 Minute Medicine




